

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

May 12, 2010  
(Date of earliest event reported)

**LABORATORY CORPORATION OF  
AMERICA HOLDINGS**

---

(Exact Name of Registrant as Specified in its Charter)

**DELAWARE**

(State or other jurisdiction  
of Incorporation)

**1-11353**

(Commission  
File Number)

**13-3757370**

(I.R.S. Employer  
Identification No.)

**358 SOUTH MAIN STREET,  
BURLINGTON, NORTH CAROLINA**

(Address of principal executive offices)

**27215**

(Zip Code)

**336-229-1127**

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. Regulation FD Disclosure

Summary information of the Company in connection with its Annual Meeting of Stockholders in Burlington, NC on May 12, 2010.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Laboratory Corporation of America Holdings  
(Registrant)

Date: May 12, 2010

By: /s/F. Samuel Eberts III  
F. Samuel Eberts III, Chief Legal Officer  
and Secretary

---

2010  
**Annual Meeting  
of Stockholders**


**May 12, 2010**



## Forward Looking Statement

This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors.

Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2009, and subsequent SEC filings.



## Leading National Lab Provider

- Fastest growing national lab
- \$55 Billion market
- Clinical, Anatomic and Genomic Testing
- Serving clients in all 50 states and Canada
- Leading clinical trials testing business




## Our Focus

- Profitable revenue growth
- IT and client connectivity
- Continue scientific leadership
- Maintain price
- Control costs



## Profitable Revenue Growth

- Target specialty physicians with breadth of menu and services
- Educate payers and physicians on value of LabCorp testing
- Leverage assets from Monogram acquisition
- Continue to improve patient experience



## IT and Client Connectivity

- Enhance online services and analytic tools
- *LabCorp Inside the Box* for superior connectivity
- Improve Patient Experience through:
  - Automated PSC workflow
  - Patient access via PHRs, online appointments
  - Enterprise services including VoIP
- Continue “open platform” strategy to maximize options for users

The screenshot displays the LabCorp patient portal interface. At the top, there is a header with navigation tabs: Quick Links, Results, Alerts, Ordering, Patients, and Administration. Below the header, the 'Alerts' section is active, showing '(345 records in total)'. It lists two alerts: '12:19:09 (12:00pm) FAX FAILED' and '12:19:09 (12:00am) FAX BATCH FAILED'. To the right of the alerts is an 'Annotations' box with a 'notes log' and a '00:00:0000 (00:00:00pm)' timestamp. Below the alerts is the 'Results Inbox' section, showing '(126 records in total)'. It features a table with columns for Folders, Date, Patient Name, Case Number, Description, Lab name, and Status. The table lists several test results for patient 'Smith, A' on '02:10:09', including 'Acute leukemia...', 'Aproximately 2%', and 'Bone Marrow Aspirate...'. The interface also includes a 'print' button and various filters and sorting options.



## Continue Scientific Leadership

- Increase esoteric testing
- Grow and enhance offerings in personalized medicine:
  - Expand outcome improvement programs
  - Develop and commercialize companion diagnostics



## Maintain Price

- Managed care stability; offsets 1.9% Medicare rate decrease
- Focus on high-value tests
- Promote outcome improvement



## Control Costs

- Continue focus on collections and bad debt reduction
- Optimize supply chain
- Use efficiency gains to improve patient experience



	Three Months Ended Mar 31,		
	2010	2009	+ / (-)
Revenue <sup>(1)</sup>	\$ 1,193.6	\$ 1,155.7	3.3%
Adjusted Operating Income	\$ 243.5	\$ 240.5	1.2%
Adjusted Operating Income Margin	20.4%	20.8%	(40) bp
Adjusted EPS <sup>(1)</sup>	\$ 1.30	\$ 1.22	6.6%
Operating Cash Flow	\$ 232.0	\$ 208.9	11.1%
Less: Capital Expenditures	\$ (24.5)	\$ (30.7)	(20.2%)
Free Cash Flow	\$ 207.5	\$ 178.2	16.4%

(1) During the quarter inclement weather reduced revenue by an estimated \$23 million and EPS by approximately eight cents


Laboratory Corporation of America  
Other Financial Information  
FY 2009 and Q1 2010  
(\$ in millions)

	<u>Q1 09</u>	<u>Q2 09</u>	<u>Q3 09</u>	<u>Q4 09</u>	<u>Q1 10</u>
Bad debt as a percentage of sales	5.30%	5.30%	5.30%	5.30%	5.05%
Days sales outstanding	52	50	48	44	46
A/R coverage (Allowance for Doubtful Accts. / A/R)	19.5%	20.6%	21.9%	23.2%	21.7%

## Superior Two-Year Return

- LabCorp shares up 4.7%
- S&P Healthcare Index down 11.3%
- S&P 500 down 16.9%
- S&P Financials Index down 42.1%

**Stock Performance: January 2008 - Present**



Source: First Call

Note: Period measured is from January 2<sup>nd</sup>, 2008 – May 3<sup>rd</sup>, 2010

## Key Points

- Critical position in health care delivery system
- Attractive market
- Strong competitive position - well positioned to gain share
- Leadership in personalized medicine
- Excellent cash flow
- Strong balance sheet



